Geron Corporation (Nasdaq:GERN) will be presenting an update of the company’s product development programs on Tuesday, May 8, 2007, at the UBS Global Generic & Specialty Pharmaceuticals Conference at 9:00 a.m. Eastern Time in New York City.

The presentation will include an update of Geron’s portfolio of telomerase-based anti-cancer therapies, including GRN163L and GRNVAC1. Alan B. Colowick, M.D., M.P.H., Geron’s president, oncology, will be giving the presentation.

The audio only webcast will be available at the following website address: www.ibb.ubs.com. To access the webcast, click the Conferences icon in the center right of the page and follow the link for Webcast located next to the Global Specialty Pharmaceuticals Conference heading. The replay will be available three hours after the live presentation and will be archived for 30 days.

For further information, please contact Geron Corporation at 650-473-7765 or visit Geron’s website at www.geron.com.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.